Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma

Xiu-Bao D Chang, Yuanxiao Zhu, Changxin Shi, Alexander Keith Stewart

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular mechanism of IMiDs' action is largely unknown. In this review, we will summarize recent advances in the application of IMiDs in MM cancer treatment as well as their effects on immunomodulatory activities, anti-angiogenic activities, intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells, anti-inflammatory activities, anti-proliferation, pro-apoptotic effects, cell cycle arrest, and inhibition of cell migration and metastasis. In addition, the potential IMiDs' target protein, IMiDs' target protein's functional role, and the potential molecular mechanisms of IMiDs resistance will be discussed. We wish, by presentation of our naive discussion, that this review article will facilitate further investigation in these fields.

Original languageEnglish (US)
Pages (from-to)240-253
Number of pages14
JournalActa Biochimica et Biophysica Sinica
Volume46
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Multiple Myeloma
Cells
Cell Migration Inhibition
Thalidomide
Oncology
Cell Adhesion Molecules
Cell Cycle Checkpoints
Mesenchymal Stromal Cells
Pharmaceutical Preparations
Bone
Proteins
Anti-Inflammatory Agents
Adhesion
Neoplasm Metastasis
Molecules
Neoplasms
lenalidomide
pomalidomide

Keywords

  • cancer treatment
  • cereblon
  • E3 ubiquitin ligase
  • immunomodulatory drugs
  • multiple myeloma

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. / Chang, Xiu-Bao D; Zhu, Yuanxiao; Shi, Changxin; Stewart, Alexander Keith.

In: Acta Biochimica et Biophysica Sinica, Vol. 46, No. 3, 03.2014, p. 240-253.

Research output: Contribution to journalArticle

@article{1c32951913a54eb8b8d9d8e6ee7579eb,
title = "Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma",
abstract = "Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular mechanism of IMiDs' action is largely unknown. In this review, we will summarize recent advances in the application of IMiDs in MM cancer treatment as well as their effects on immunomodulatory activities, anti-angiogenic activities, intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells, anti-inflammatory activities, anti-proliferation, pro-apoptotic effects, cell cycle arrest, and inhibition of cell migration and metastasis. In addition, the potential IMiDs' target protein, IMiDs' target protein's functional role, and the potential molecular mechanisms of IMiDs resistance will be discussed. We wish, by presentation of our naive discussion, that this review article will facilitate further investigation in these fields.",
keywords = "cancer treatment, cereblon, E3 ubiquitin ligase, immunomodulatory drugs, multiple myeloma",
author = "Chang, {Xiu-Bao D} and Yuanxiao Zhu and Changxin Shi and Stewart, {Alexander Keith}",
year = "2014",
month = "3",
doi = "10.1093/abbs/gmt142",
language = "English (US)",
volume = "46",
pages = "240--253",
journal = "Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica",
issn = "1672-9145",
publisher = "Shanghai Kexue Jishu Chubanshe/Shanghai Scientific & Technical Publishers",
number = "3",

}

TY - JOUR

T1 - Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma

AU - Chang, Xiu-Bao D

AU - Zhu, Yuanxiao

AU - Shi, Changxin

AU - Stewart, Alexander Keith

PY - 2014/3

Y1 - 2014/3

N2 - Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular mechanism of IMiDs' action is largely unknown. In this review, we will summarize recent advances in the application of IMiDs in MM cancer treatment as well as their effects on immunomodulatory activities, anti-angiogenic activities, intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells, anti-inflammatory activities, anti-proliferation, pro-apoptotic effects, cell cycle arrest, and inhibition of cell migration and metastasis. In addition, the potential IMiDs' target protein, IMiDs' target protein's functional role, and the potential molecular mechanisms of IMiDs resistance will be discussed. We wish, by presentation of our naive discussion, that this review article will facilitate further investigation in these fields.

AB - Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular mechanism of IMiDs' action is largely unknown. In this review, we will summarize recent advances in the application of IMiDs in MM cancer treatment as well as their effects on immunomodulatory activities, anti-angiogenic activities, intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells, anti-inflammatory activities, anti-proliferation, pro-apoptotic effects, cell cycle arrest, and inhibition of cell migration and metastasis. In addition, the potential IMiDs' target protein, IMiDs' target protein's functional role, and the potential molecular mechanisms of IMiDs resistance will be discussed. We wish, by presentation of our naive discussion, that this review article will facilitate further investigation in these fields.

KW - cancer treatment

KW - cereblon

KW - E3 ubiquitin ligase

KW - immunomodulatory drugs

KW - multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84897722338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897722338&partnerID=8YFLogxK

U2 - 10.1093/abbs/gmt142

DO - 10.1093/abbs/gmt142

M3 - Article

VL - 46

SP - 240

EP - 253

JO - Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica

JF - Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica

SN - 1672-9145

IS - 3

ER -